. Mechanistic in vitro cellular activity of AZD1390. (A) AZD1390 inhibits ATM activity and downstream markers (pKAP-1 and pCHK-2) in cell at 10nM and above in mutant p53 LN18 cells, with 1, 4 and 24hrs of drug exposure. (B) ATM-dependent target engagement and selectivity against DNA-PK phosphorylation by AZD1390 in NCIH2228 cells (in vivo lung-brain metastatic model) and (C) Dose response of ATM-dependent target engagement at lower doses of AZD1390 and selectivity against DNA-PK and ATR phosphorylation in NCIH2228 cells (in vivo lung-brain metastatic model). Table 3 . * and **indicates a significant difference from the IR alone group with p<0.05 and p<0.01 respectively. 
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fig. S5. PK and PD study of single-dose AZD1390 plus IR in NCI-H2228 ICB model (ICCIN-2012). (A) AZD1390 plus IR on the effect of tumor growth inhibition in NCI-H2228 brain metastasis model by ICB injection (ICCIN-1968). (B) Survival benefit of AZD1390 plus IR in NCI-H2228 brain metastasis model by ICB injection (ICCIN-
1968
